創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 技術番号 技術名 技術概要
19/08/21 TGEM031 Delivery of anticancer drugs to cancer cells
TGEM031 is a modified β-Cyclodextrin and increased in vitro antitumor activities of doxorubicin (DOX), vinblastine and paclitaxel. The complex of DOX with TGEM031 markedly increased antitumor activity of DOX, after intravenous administration to tumor-bearing mice. 問合せ
19/07/31 TGEM030 Innovative technology enabling improved GI absorption of the insoluble drug
A patented technology based on lipidic compositions which form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. TGEM030 enables development of superior oral products with: Improved solubilization and high drug loading capacity, improved bioavailability, faster and more consistent absorption leading to reduced variability and reduced sensitivity to food effects. TGEM030 utilizes bioacceptable excipients and conventional manufacturing processes.
問合せ
19/07/08 TGEM029 Sustained release PLGA
Poly lactide-co-glycolide acid (PLGA) microsphere technology for sustained release of drugs. Versatile drug release profiles could be achieved by adjusting the formulation compositions and effective plasma drug concentration could be maintained for several weeks or months upon one injection. In addition, the pharmacokinetic and pharmacodynamics evaluation models for sustained release technology have been established which could speed up product development. 問合せ
19/07/08 TGEM028 Posterior eye delivery
An ocular delivery technology specially designed to topically deliver hydrophobic small molecular across ocular tissues into posterior ocular tissues.
The eye drop based delivery technology can overcome the delivery obstacle of tissue barriers to transport therapeutics to posterior ocular target tissue. This breakthrough technology is expected to bring broader applications for posterior ocular drug delivery
問合せ
19/07/08 TGEM027 Site-specific linker toxin
The disadvantages of traditional conjugation technologies include the lack of specificity at the connecting positions of the antibodies and the variable number of connections. The new technology can overcome these disadvantages by improving homogeneity of ADC via site-specific conjugation. The site-specific linker-toxin shows better homogeneity, stability and efficacy. 問合せ
19/07/08 TGEM026 Intracellular delivery
This technology enables peptide and oligonucleotide drugs to be delivered efficiently into cells through conjugating a cell-penetrating motif (CPM) onto drug candidate. Unlike liposomal or other nanoparticle formulation, the CPM technology requires no encapsulation process and provides formulated drug product with high stability and storage condition tolerances. 問合せ
19/06/06 TGEM025 Innovative proteoliposome methodology for rapid discovery of biomarkers, ligands and/or receptors
A newly developed one-step direct transfer technology for MALDI-mass spectrometry (MS) can eliminate time-consuming intermediate processes and separate or remove plasma high abundant proteins, and therefore is useful for rapid and efficientt peptide profiling of biological samples. In addition, this technology can be used for rapid identification of ligands and cell surface receptors including GPCRs and GPI anchors by combining with a library of membrane proteins keeping binding capability reconsitututed on artificial phopholipid bilayers of liposomes. 問合せ
19/05/30 TGEM024 Novel lymphatic delivery system
A novel hyaluronic acid-based nanocarriers that could deliver more drug to lymph nodes.
This delivery system may offer significant advantages for the use of platinum medicines in the management of locally advanced cancers.
Organic solvent-free nanocarriers process.
Active targeting to lymph node and tumor.
問合せ
19/05/30 TGEM023 Innovative formulation for insoluble drugs
Novel platform of formulation design and evaluation include concept of formulation design, composition of formulation, in vitro dissolution study, and in vivo absorption test. This new concept of formulation design utilizes solubility buster with traditional excipient to resolve solubility problem of drugs. This platform could be widely applied to BCS II drugs and shorten development process. Traditional excipient and solubility buster are commercial products that are easy to purchase without limitation. 問合せ
19/04/02 TGEM022 Innovative nanoparticle formulation
Achieved higher content of drug, more homogeneous particle size distribution, lower cost (1/10) and easier mass production compared to conventional methods.
Easy to control particle size (2 nm ~ 500 nm).
Provide DDS function to the drug and stay the drug in the cell for a long time.
Enable re-development of compounds that abandon development with side effects and insufficient effect.
The substrate used in the nanoparticle formulation are used in approved medicines (FDA).
問合せ